Pilot study evaluating 1,3-bis(2-chloroethyl)-1-nitrosourea in the treatment of advanced ovarian carcinoma. 1973

E O Jorgensen, and G D Malkasian, and M J Webb, and R G Hahn

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013921 Thrombocytopenia A subnormal level of BLOOD PLATELETS. Thrombopenia,Thrombocytopenias,Thrombopenias
D014839 Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH. Emesis

Related Publications

E O Jorgensen, and G D Malkasian, and M J Webb, and R G Hahn
February 1973, American journal of obstetrics and gynecology,
E O Jorgensen, and G D Malkasian, and M J Webb, and R G Hahn
June 1972, Lancet (London, England),
E O Jorgensen, and G D Malkasian, and M J Webb, and R G Hahn
August 1971, The New England journal of medicine,
E O Jorgensen, and G D Malkasian, and M J Webb, and R G Hahn
June 1995, Mutation research,
E O Jorgensen, and G D Malkasian, and M J Webb, and R G Hahn
January 1965, Antimicrobial agents and chemotherapy,
E O Jorgensen, and G D Malkasian, and M J Webb, and R G Hahn
October 1979, Journal of medicinal chemistry,
E O Jorgensen, and G D Malkasian, and M J Webb, and R G Hahn
October 1984, Fundamental and applied toxicology : official journal of the Society of Toxicology,
E O Jorgensen, and G D Malkasian, and M J Webb, and R G Hahn
April 1972, Cancer chemotherapy reports,
E O Jorgensen, and G D Malkasian, and M J Webb, and R G Hahn
December 1980, Neurosurgery,
E O Jorgensen, and G D Malkasian, and M J Webb, and R G Hahn
July 1965, Applied microbiology,
Copied contents to your clipboard!